Company Filing History:
Years Active: 1996-1999
Title: Innovations of Markus Zwickl in Recombinant Antibodies
Introduction
Markus Zwickl is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant antibodies. With a total of 2 patents, his work focuses on advancements that have the potential to impact cancer diagnosis and treatment.
Latest Patents
Zwickl's latest patents revolve around recombinant antibodies specific for the growth factor receptor c-erbB-2. These inventions include antibodies directed to the extracellular domain of the human growth factor receptor, which comprise both light chain and heavy chain variable domains of monoclonal antibodies. His patents detail methods for manufacturing these recombinant antibodies and monoclonal antibodies, as well as the creation of hybridoma cells that secrete these antibodies. Additionally, Zwickl's work encompasses DNA coding for the variable domains and the recombinant antibody, methods for manufacturing this DNA, and hybrid vectors suitable for its expression. The applications of these antibodies are significant in the diagnosis and treatment of tumors.
Career Highlights
Throughout his career, Markus Zwickl has worked with prominent companies in the pharmaceutical industry, including Ciba-Geigy Corporation and Novartis Corporation. His experience in these organizations has contributed to his expertise in the field of antibody development and biotechnology.
Collaborations
Zwickl has collaborated with esteemed colleagues such as Winfried Stephan Wels and Nancy E. Hynes. These partnerships have likely enhanced his research and development efforts in the field of recombinant antibodies.
Conclusion
Markus Zwickl's innovations in recombinant antibodies represent a significant advancement in biotechnology. His contributions have the potential to improve cancer diagnosis and treatment, showcasing the importance of his work in the medical field.